treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra... for employment without regard to race, ethnicity, color, religion, sex gender identity, sexual orientation, national origin, age...
. Distinguishing Characteristics of this Level N/A Job Level: F2 Duke is an Affirmative Action/Equal Opportunity Employer... expression, gender identity, genetic information, national origin, race, religion, sex, sexual orientation, or veteran status...
treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra..., sexual orientation, national origin, age, disability, protected veteran or disabled status, or other characteristic protected...
Job Level: F2 Revised Date: 09/01/2025 Supervisory Responsibility: No ~ ~ General Description of the Job Class..., color, disability, gender, gender expression, gender identity, genetic information, national origin, race, religion, sex...
treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra... consideration for employment without regard to race, ethnicity, color, religion, sex gender identity, sexual orientation, national...
treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra... gender identity, sexual orientation, national origin, age, disability, protected veteran or disabled status...
treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra... by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase...
treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra..., sexual orientation, national origin, age, disability, protected veteran or disabled status, or other characteristic protected...
treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra... consideration for employment without regard to race, ethnicity, color, religion, sex gender identity, sexual orientation, national...
treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra..., sexual orientation, national origin, age, disability, protected veteran or disabled status, or other characteristic protected...